Pan-Asia Catalysts/Events, Quiddity Advisors

David Blennerhassett

HK Type 4 license through Ballingal Investment Advisors Ltd. 

I'm a highly experienced sell-side analyst with in excess of 22 years of covering Asia Pacific equities, the past 19 years immersed in event strategies encompassing M&A risk arbitrage, directional long/short, stub trades and restructuring.  

My background also includes accountancy (liquidation/bankruptcy/receivership) earlier in my career and as a chief financial officer of a global commodity company based in the US and Mexico.

Pan-Asia Catalysts/Events

Quiddity Advisors

Event-Driven

<ul>
<li>Disappointingly, the sensitivity and specificity of <strong><a href="https://www.smartkarma.com/entities/narhex-life-sciences-ltd" target="_blank" data-smartkarma-citation="entities:9728:1" rel="noopener">ResApp Health (RAP AU)</a></strong>'s cough trial were significantly lower than its March pilot study.</li>
<li>As such, the Scheme Consideration from <strong><a href="https://www.smartkarma.com/entities/pfizer-inc" target="_blank" data-smartkarma-citation="entities:1131:1" rel="noopener">Pfizer Inc (PFE US)</a> </strong>will be A$0.146/share, which is still a 62.2% premium to the undisturbed price.</li>
<li>Trading super wide to terms after short-term punters kicked out. </li>
</ul>


Disappointingly, the sensitivity and specificity of ResApp Health (RAP AU)'s cough trial were significantly lower than its March pilot study.
As such, the Scheme Consideration from Pfizer Inc (PFE US) will be A$0.146/share, which is still a 62.2% premium to the undisturbed price.
Trading super wide to terms after short-term punters kicked out. 


ResApp (RAP AU): Low-End Pfizer Offer As Cough Trial Fails

Resapp Health

ResApp (RAP AU): Low-End Pfizer Offer As Cough Trial Fails